MAZE: Maze Therapeutics, Inc. insider trading, 5% holders and institutional ownership
From public SEC filings: open-market insider purchases and sales (Form 4, last 180 days), holders of 5% or more (Schedules 13D and 13G) and institutional ownership (Form 13F). Insider and 5% data delayed 48 hours.
Insider trading
0 open-market buys totaling - and 4 sales totaling $1.57M in the last 180 days.
Insider sales
| Trade date | Insider | Role | Value | 10b5-1 plan |
|---|---|---|---|---|
| 2026-10-01 | Bernstein Harold | President | $435K | yes |
| 2026-10-01 | Coloma Jason V | CEO | $70K | yes |
| 2026-10-01 | Coloma Jason V | CEO | $862K | yes |
| 2026-09-29 | Dandekar Atul | Officer | $203K | yes |
Activist and 5% holders
| Filed | What | Holder | Stake | Change | Filing |
|---|---|---|---|---|---|
| 2026-08-14 | Fell below 5% | Paradigm BioCapital Advisors LP | 0.00% | SEC |
Get new insider and activist filings the morning after: daily alerts. Not investment advice.